Skip to main content

Vanda Pharmaeuticals says Hetlioz is a big step closer to addressing jet lag disorder – Washington Business Journal

By March 12, 2018News
Vanda-Pharmaceuticals-logo

Vanda-Pharmaceuticals-logo

Millions of travelers suffer from jet lag every year. And now Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) said one of its drugs successfully addressed the problem with hundreds of volunteers in a late-stage clinical trial.

{iframe}https://www.bizjournals.com/washington/news/2018/03/05/a-drug-for-jet-lag-a-d-c-drug-developer-says-it.html{/iframe}

Leave a Reply

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.